



21st April, 2025

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 974556, 975834 and 976560 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: PRESS RELEASE REGARDING COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SITE, CHINA

REF.: i) DISCLOSURE UNDER REGULATIONS 30 AND 51 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

ii) OUR LETTER DATED 9TH APRIL, 2025 REGARDING REGULATIONS 30 AND 51: COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SITE, CHINA

Dear Sir,

In furtherance to our intimation dated 9th April, 2025, pleased find enclosed herewith Press Release regarding the Company’s wholly owned subsidiary namely CARBOGEN AMCIS (Shanghai) Co. Ltd., has received Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai, China.

Kindly take this on your record.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As Above

PRESS RELEASE

The Company announces that its subsidiary, CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA

Ahmedabad, India (April 21, 2025) — the Company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA).

The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region.

Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m² site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide.

"This achievement underscores our team's commitment, disciplined execution, and the robustness of our Quality Management System, which has been rigorously aligned with both corporate and Chinese regulatory requirements," said **Simone Maggi, Quality Head - CARBOGEN AMCIS Shanghai site.**

"In addition to our core manufacturing capabilities, we're proud that the Shanghai site is equipped to handle highly potent compounds up to category 3 and provide full GMP product release and analytical support," said **Harry Wong, Country Manager, CARBOGEN AMCIS Shanghai.** "This license is a testament to the strength of our team and demonstrates our ability to execute seamless technology transfers and align with the highest quality standards across CARBOGEN AMCIS' global network."

Stephan Fritschi, CEO at CARBOGEN AMCIS, stated: "Securing the Drug Manufacturing License not only demonstrates the operational readiness of our Shanghai site but also reflects the strength of our global quality culture. This achievement strengthens our long-term goal of becoming a trusted partner in the Chinese pharmaceutical market." He added, "I would like to take this opportunity to express my gratitude to every member of our site team for their dedication and to the Executive Team for their continuous support and trust throughout this journey."

-- ENDS --

For further information contact:

Denise Neufeld +41 79 213 06 60

Denise.Neufeld@carbogen-amcis.com

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers' businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.